Next 10 |
– SENTI-202 is a potential first-in-class Logic Gated off-the-shelf CAR-NK cell therapy – – Initial clinical efficacy data expected by year-end 2024 and durability data expected in 2025 – SOUTH SAN FRANCISCO, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Sen...
2024-05-10 07:46:46 ET More on Senti Biosciences Financial information for Senti Biosciences Read the full article on Seeking Alpha For further details see: Senti Biosciences GAAP EPS of -$0.26
– First patient dosing of SENTI-202, a first-in-class logic-gated treatment for acute myeloid leukemia (“AML”), on track for the second quarter of 2024 – SOUTH SAN FRANCISCO, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) ( ...
A look at the top 10 most actives in the United States Next.e.GO N.V. (EGOX) rose 38.0% to $0.0381 on volume of 59,468,925 shares Greenwave Technology Solutions Inc. (GWAV) rose 1.5% to $0.066 on volume of 45,683,331 shares Global Mofy Metaverse Limited (GMM) rose 68.4% to $1.5667 on volu...
– Preclinical data demonstrates the potential for improved treatment outcomes and reduced toxicity for patients with AML – – Data supports the design of Phase 1 clinical trial of SENTI-202 with patient dosing anticipated in the second quarter of 2024 – ...
– IND for SENTI-202, a potential first-in-class logic-gated treatment for AML, cleared by the U.S. FDA; First patient dosing anticipated in the second quarter of 2024 – – Cash and anticipated receivables from GeneFab transaction expected to fund operations into the ...
2024-01-05 16:15:54 ET More on Senti Biosciences Senti Biosciences GAAP EPS of -$0.77 misses by $0.33 Senti stock soars 175% on Chinese development deal for cancer drug Seeking Alpha’s Quant Rating on Senti Biosciences Historical earnings data for Sent...
– Strategic resource allocation to focus investment on clinical development of SENTI-202 and SENTI-301A partnership in China; interim data from Phase 1 clinical trial of SENTI-202 expected in 2H 2024 – – Anticipated cost savings, which includes an approximately 37% ...
2023-12-22 12:23:57 ET DENVER, Colo., Dec. 22, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual midday volume; Royalty Management Holding Corp (NASDAQ: RMCO), Senti Biosciences Inc (NASDAQ: SNTI), Polished.com Inc...
2023-12-22 09:51:52 ET DENVER, Colo., Dec. 22, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual volume; Royalty Management Holding Corp (NASDAQ: RMCO), Senti Biosciences Inc (NASDAQ: SNTI), Cidara Therapeutics Inc...
News, Short Squeeze, Breakout and More Instantly...
Senti Biosciences Inc. Company Name:
SNTI Stock Symbol:
NASDAQ Market:
– SENTI-202 is a potential first-in-class Logic Gated off-the-shelf CAR-NK cell therapy – – Initial clinical efficacy data expected by year-end 2024 and durability data expected in 2025 – SOUTH SAN FRANCISCO, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Sen...
– First patient dosing of SENTI-202, a first-in-class logic-gated treatment for acute myeloid leukemia ("AML"), on track for the second quarter ...
– First patient dosing of SENTI-202, a first-in-class logic-gated treatment for acute myeloid leukemia (“AML”), on track for the second quarter of 2024 – SOUTH SAN FRANCISCO, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) ( ...